Oxaliplatin (Eloxatin, Oxaliplatin Medac)

Indications

Cytokine Release Syndrome (see Cytokine Release Syndrome, [[Cytokine Release Syndrome]])
Severe Anaphylaxis (see Anaphylaxis, [[Anaphylaxis]]): occurs in 1.3% of cases

Ototoxicity: rare with oxaliplatin (in contrast to cisplatin)
Peripheral Neuropathy (see Peripheral Neuropathy, [[Peripheral Neuropathy]])
- Acute Neurotoxicity: likely due to calcium chelation by oxalate (a metabolite of oxaliplatin) -> activation of disinhibited peripheral nerve voltage-gated calcium-dependent sodium channels and disruption in cell membrane ion channels, resulting in hyperexcitability of peripheral nerves
  - Cold-Induced Peri-Oral Parasthesias
  - Cold-Induced Pharyngolaryngeal Dysesthesia (“Pseudolaryngospasm”)
  - Dysphagia (see Dysphagia, [[Dysphagia]])
  - Dyspnea (see Dyspnea, [[Dyspnea]])
  - Fasciculations (see Fasciculations, [[Fasciculations]])
  - Jaw Stiffness
  - Muscle Cramps
  - Ocular Changes
  - Voice Changes
- Cumulative Sensory Neuropathy
Posterior Reversible Encephalopathy Syndrome (PRES) (see Posterior Reversible Encephalopathy Syndrome, [[Posterior Reversible Encephalopathy Syndrome]])

Acute Lung Injury-ARDS (see Acute Lung Injury-ARDS, [[Acute Lung Injury-ARDS]]): diffuse alveolar damage has been reported to occur in combination with 5-fluorouracil (see 5-Fluorouracil, [[5-Fluorouracil]])
Drug-Induced Pulmonary Eosinophilia (see Drug-Induced Pulmonary Eosinophilia, [[Drug-Induced Pulmonary Eosinophilia]])

Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. Journal of Biological Regulators and Homeostatic Agents 2002, 16(2):105-9 [MEDLINE]